SCHEMBL13699019

SCHEMBL13699019

COc1ccc2c(c1)COCCN2C(C)=O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.68
HSD17B10 Q99714 1/20 0.50
TRIM24 O15164 4/20 0.49
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
HSD17B3 P37058 1/20 0.45
POLB P06746 3/20 0.45
KMT2A Q03164 3/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TP53 P04637 1/20 0.44
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206878 0.81 NOTUM (1.00) NOTUMHSD17B10TRIM24CYP11B1CYP11B2
SCHEMBL2203840 0.79 NOTUM (0.83) NOTUMHSD17B10TRIM24POLBKMT2A
SCHEMBL13699025 0.78 NOTUM (0.60) NOTUMHSD17B3POLBKMT2AMEN1
SCHEMBL6985785 0.75 KMT2A (0.60) NOTUMPOLBKMT2AMEN1MAPT
Trifluoroacetic Acid SCHEMBL31438768 0.74 NOTUM (0.82) NOTUMHSD17B10TRIM24CYP11B1CYP11B2
SCHEMBL13699015 0.73 NOTUM (0.57) NOTUMHSD17B10TRIM24HSD17B3POLB
SCHEMBL2208006 0.73 NOTUM (0.78) NOTUMHSD17B10TRIM24CYP11B1CYP11B2
SCHEMBL21172770 0.71 NOTUM (0.62) NOTUMHSD17B10TRIM24CYP11B1CYP11B2
SCHEMBL23090380 0.69 NOTUM (0.63) NOTUMHSD17B10POLBLMNAMAPT
SCHEMBL5567815 0.69 NOTUM (0.76) NOTUMHSD17B10TRIM24CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R NOTUM 2609/4885HSD17B10 3929/4885TRIM24 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.